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Abstract
Background: To evaluate the midterm results of percutaneous cryoablation for medically inoperable stage I non-small cell
lung cancer.
Methodology/Principal Findings: Between January 2004 and June 2010, 160 patients underwent computer tomography
guided percutaneous cryoablation for lung tumors at our institution. Of these patients, histologically proven stage I lung
cancer patients with more than one year of follow-up, were retrospectively reviewed. All of these patients were considered
to be medically inoperable with Charlson comorbidity index of 3 or greater. Follow-up was based primarily on computed
tomography. There were 22 patients with 34 tumors who underwent 25 sessions of cryoablation treatment. Complications
were pneumothoraces in 7 treatments (28%, chest tube required in one treatment), and pleural effusions in 8 treatments
(31%). The observation period ranged from 12–68 months, average 29619 months, median 23 months. Local tumor
progression was observed in one tumor (3%). Mean local tumor progression-free interval was 6962 months. One patient
died of lung cancer progression at 68 months. Two patients died of acute exacerbations of idiopathic pulmonary fibrosis
which were not considered to be directly associated with cryoablation, at 12 and 18 months, respectively. The overall 2- and
3-year survivals were 88% and 88%, respectively. Mean overall survival was 6264 months. Median overall survival was 68
months. The disease-free 2- and 3-year survivals were 78% and 67%, respectively. Mean disease-free survival was 4666
months. Pulmonary function tests were done in 16 patients (18 treatments) before and after cryoablation. Percentage of
predicted vital capacity, and percentage of predicted forced expiratory volume in 1 second, did not differ significantly
before and after cryoablation (93623 versus 90621, and 70611 versus 70612, respectively).
Conclusions/Significance: Although further accumulation of data is necessary regarding efficacy, cryoablation may be a
feasible option in medically inoperable stage I lung cancer patients.
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Introduction
Surgical resection is currently the standard treatment for stage I
non-small cell lung cancer (NSCLC). However, in patients who
are medically inoperable due to significant comorbidities, other
treatment modalities need to be considered. The non-surgical
management of early stage lung cancer is currently an expanding
field. These include stereotactic body radiation therapy (SBRT)
and thermal ablative procedures such as radiofrequency ablation
(RFA) and microwave ablation [1,2,3,4,5,6]. Percutaneous
cryoablation is also currently evolving as a minimally invasive,
and potentially effective, local treatment for lung tumors
[7,8,9,10]. This procedure, mostly used when surgical resection
is contraindicated, is currently under evaluation as a potential
complementary therapy for patients with primary lung cancers as
well as metastatic lung tumors. We have, to date, treated more
than 300 lung tumors in more than 200 patients with acceptable
feasibility and efficacy. Of these patients, in the present study, we
retrospectively analyzed the midterm outcomes of stage I NSCLC
patients treated with cryoablation.
Materials and Methods
Ethics
This study protocol was approved by Keio University
institutional review board (approval ID: 14–23). Written informed
consent was obtained from each participant in accordance with
the Declaration of Helsinki.
Selection of patients
Between January 2004 and August 2010, 160 patients
underwent cryoablation for lung tumors at our institution. Of
these patients, we retrospectively reviewed our experience with
cryoablation for the primary treatment of stage I NSCLC in
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up. The tumors which presented as multiple tumors in one patient,
were clinically considered as synchronous or metachronous
primary lung cancers to be eligible for this study. Some of these
patients have been reported previously [7,9].
Prior to considering cryoablation, patients with histologically
diagnosed NSCLC were routinely staged with chest-to-pelvis
computed tomography (CT), brain magnetic resonance imaging
(MRI) or CT, and most of the patients also underwent a positron
emission tomographic (PET) scan. Bone scintigraphy was done if
PET scan was not performed. Patients with hilar or mediastinal
lymph nodes greater than 1 cm in the shortest axis, a positive PET
scan result, or both, underwent endobronchial ultrasonography
guided needle biopsy, or mediastinoscopy.
The inclusion criteria for this study were patients who were
considered medically inoperable because of risks such as impaired
cardiac function, poor pulmonary function, and/or other
comorbidities, i.e., Charlson comorbidity index (CCI) [11]
.=3. The patients’ desires to avoid surgery in association with
their medical comorbidities were also accounted for. The
exclusion criteria were as follows: (1) Eastern Cooperative
Oncology Group (ECOG) score of 2 or more. (2) Platelet count
of less than 50,000/mL. (3) Prothrombin time international
normalized ratio of more than 1.5. (4) No suitable way for the
insertion of probes due to interference by major vasculatures,
airways or mediastinal structures. (5) Incapable of cooperation
during the cryoablation procedure. All patients were evaluated by
representatives from pulmonologists, interventional radiologists,
and thoracic surgeons to determine inoperability and suitability for
cryoablation.
Cryoablation procedure
The procedure of percutaneous cryoablation was performed
under local anesthesia as previously described [7]. Under a
multidetector-row CT scanner with multi-slice CT fluoroscopy
functions (Aquilion 64; Toshiba Med. Co. Ltd., Tokyo, Japan),
using an outer insertion sheath, a 1.7-mm-diameter cryoprobe
(CRYOcare Cryosurgical Unit; Endocare, Irvine, CA) was
inserted into the targeted nodule under fluoroscopic CT guidance.
Multiple probes were simultaneously inserted if the ablation
margin was considered to be insufficient with just one probe. The
cryoprobe uses high-pressure argon and helium gases for freezing
and thawing, respectively, based on the Joule-Thompson princi-
ple. Cryoablation consisted of three cycles of freezing, 5, 10, and
10 minutes each. The tip of the cryoprobe reaches approximately
2130uC during freezing. This was followed by thawing until the
temperature of the cryoprobe reached 20uC, and then a third cycle
of freezing (10 minutes) followed by thawing. Fibrin glue was
infused into the outer sheath at the time of cryoprobe removal to
reduce the risks of hemothoraces and pneumothoraces. Whole
lung CT scans were taken at the ends of each of the procedures.
Chest radiographs were also taken two hours after, the next day,
and the day after each of the procedures to check for
complications such as hemothoraces or pneumothoraces. The
patients were discharged on the second postoperative day if there
were no complications.
Follow-up after cryoablation
Follow-up chest-to-pelvis CT scans with contrast enhancement
were carried out at 1-month and then at 3 to 6 months intervals
after cryoablation. We confirmed local progression when there was
a continuous focal or diffuse enlargement of the ablated lesion on
CT. Furthermore, even when no enlargement was seen, we
regarded it as local progression if the size of partial enhancement
in the tumor continuously increased. As for the detection of distant
metastases, brain MRI or CT was done every 3 to 6 months. PET
scan or bone scintigraphy was done if considered to be necessary.
Pulmonary function test
Pulmonary function test was done in patients who could
adequately perform the test, before, and 3 to 6 months after
cryoablation.
Statistical methods
Local tumor progression–free intervals, and overall and disease-
free survivals, were calculated with the Kaplan–Meier method.
Pulmonary function tests were compared with the paired t test.
The statistical software package SPSS 17.0 (SPSS Inc, Chicago, Ill)
was used for all analyses. P values smaller than 0.05 was
considered to be statistically significant.
Results
During the study period, 22 patients with 34 tumors underwent
25 sessions of lung cryoablation treatments for clinical stage I
NSCLC. These patients were retrospectively reviewed. None of
the patients had mediastinal or hilar lymph nodes greater than
1 cm in the shortest axis, or a positive PET scan result of the
mediastinal or hilar lymph nodes. Fifteen patients had single
tumors, which were all treated in one session. Three patients had 2
tumors. The 2 tumors were found synchronously in all 3 patients,
and were treated as one session per patient. Four patients had 3
tumors. In 2 of these patients, the 3 tumors were found
synchronously, and were treated as one session per patient. In
both of the remaining 2 patients, 2 tumors were synchronous and
one was metachronous. The 2 synchronous tumors were treated in
one session in each of the patients. The metachronous tumors
were treated as another session in both patients. One patient had 4
tumors. Two of these tumors were found synchronously and were
treated in one session. Other 2 metachronous tumors were found
at the same time, and were treated in one session. The patient and
tumor characteristics are described in Table 1. The mean maximal
tumor diameter was 1.460.6 cm (range 0.5–3.0 cm). More than
half of the patients had a past history of resection for another lung
cancer. Majority of tumors were adenocarcinomas. Nine patients
had more than one tumor, which were considered to be
synchronous, or metachronous primary lung cancers. The number
of probes used was 1 in 20 tumors, 2 in 13 tumors, and 3 in 1
tumor. Eight patients (36%) had significant cardiac or vascular
disease that put them at high risk for surgical resection. Limited
pulmonary function was the predominant determinant of medical
inoperability in 6 patients (27%). Four of these patients were on
oxygen therapy. Other comorbidities included renal dysfunction,
liver dysfunction, and concomitant malignancies. Average CCI
was 563, range 3 to 15.
The most common complications of cryoablation were
pneumothoraces, minor hemoptyses, and pleural effusions.
Pneumothoraces were seen in 7 treatments (28%). Pleural effusions
were seen in 8 treatments (31%). Minor hemoptyses were seen in 6
patients (24%). Chest tube insertion was required in one patient
with pneumothorax. All other complications resolved with
observation only.
The observation period ranged from 12–68 months, average
29619 months, median 23 months. Local tumor progression after
cryoablation was observed in one tumor (3%) which was a
squamous cell carcinoma 1.6 cm in size. Local failure was
recognized as progressive enlargement of the ablated region at 8
months after cryoablation. At this time, no other metastases were
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months after re-cryoablation, the patient developed an upper
respiratory infection, which lead to an acute exacerbation of the
underlying idiopathic pulmonary fibrosis (IPF). The patient
subsequently died of the acute exacerbation. At this point, local
control was maintained. Overall, the mean local tumor progres-
sion-free interval was 6962 months. Median local tumor
progression-free interval was not reached (Figure 1A).
So far 3 patients (14%) have died. One patient was the patient
described above. Another patient died of lung cancer 68 months
after cryoablation. This patient developed multiple systemic
metastases whereas local control was maintained. This patient
received chemotherapy one year after cryoablation because distant
metastases were detected. The remaining one patient died of acute
exacerbation of IPF 18 months after cryoablation. In this case, the
acute exacerbation of IPF occurred immediately after chemother-
apy for concomitant liver cancer, and was not considered to be
directly associated with lung cryoablation. There are 2 patients
who have received chemotherapy and are alive. One patient
developed multiple lung metastasis 48 months after cryoablation
and have received systemic therapy with gefitinib. Local control
was maintained in this patient. The other patient developed
multiple systemic metastases 4 months after cryoablation. Local
control was maintained. This patient received systemic chemo-
therapy after detection of distant metastases. The overall 2- and 3-
year survivals were 88% and 88%, respectively. Mean overall
survival was 6264 months. Median overall survival was 68 months
(Figure 1B). Five patients are alive with lung cancer. The disease-
free 2- and 3-year survivals were 78% and 67%, respectively.
Mean disease-free survival was 4666 months. Median disease-free
survival was not reached (Figure 1C).
The patterns of recurrences other than local recurrence were as
follows: Recurrence only in the ipsilateral thorax was seen in 1
patient, which was lung metastases. Needle-tract disseminations or
pleural recurrences have not been detected so far in any of the
patients. Distant metastases were seen in 5 patients. These
included metastases to contralateral thoraces, lumbar vertebra,
ribs, and brain. Treatments for these patients included chemo-
therapy, radiation, and gamma-knife.
Pulmonary function was evaluated in 16 patients (18 treatments)
before and 3 to 6 months after cryoablation. There were no
significant differences before and after cryoablation in vital
capacity (2.7260.82 L versus 2.6460.74 L, p=0.19), percentage
of predicted vital capacity (93623% versus 90621, p=0.11),
forced expiratory volume in 1 second (1.8160.53 L versus
1.7760.50 L, p=0.14) (Figure 2), and percentage of forced
expiratory volume in 1 second (70611% versus 70612%,
p=0.95).
Discussion
There is accumulating evidence that RFA is a safe and feasible
treatment option for the treatment of inoperable stage I NSCLC.
There is one report in which the results of cryoablation for stage I
lung cancer is included among the results of RFA and sublobar
resections [10]. But to our knowledge, this is the first report which
specifically focuses on cryoablation in patients with medically
inoperable stage I NSCLC. In the present study, cryoablation was
done safely in all patients. Reduction in pulmonary function after
cryoablation was also minimal in this study, although the
pulmonary function test was done mostly in patients with relatively
good pulmonary functions who could adequately perform the test.
Figure 1. Kaplan–Meier estimate curves of (A) local progression-free interval after cryoablation, (B) overall survival after
cryoablation, and (C) disease-free survival after cryoablation.
doi:10.1371/journal.pone.0033223.g001
Table 1. Patient and tumor characteristics.
Sex (female/male) 11:11
Age (y, median) 72
Lesion size (cm)
Mean 6 SD 1.460.6
Range 0.5–3.0
Previous lung cancer resection 12 (57%)
Patients with more than one lesion 9 (43%)
ECOG PS score
01 0
11 2
Charlson comorbidity score
Mean 6 SD 5.062.9
Range 3–15
Clinical stage
T1aN0 29
T1bN0 5
Histologic type
Squamous 2
Adenocarcinoma 30
Large cell carcinoma 1
Non-small cell lung carcinoma 1
Subsolid nodules 12
doi:10.1371/journal.pone.0033223.t001
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pneumothoraces, and pleural effusions, were comparable to those
previously reported for RFA [5,6,12,13,14].
The reported local control rates for RFA treatment of
inoperable stage I NSCLC ranged from 58 to 69%
[5,6,12,13,14]. The local control rate was slightly higher in the
present study (97%), presumably because in our study the tumors
were 3 cm or less, actually mostly 2 cm or less, whereas previous
RFA studies included tumors which were 4 cm or less. As for the
one patient with local recurrence, we speculate that the primary
cause of local progression was insufficient margin of ablation.
Although 2 probes were used in this case, it was difficult to
delineate the relationship between the margin of ablation and the
margin of the tumor on CT because of the underlying IPF. We
consider that further accumulation of experience is necessary to
improve treatment outcomes in such cases. The overall and
disease-free survival at 3 years were better than that previously
reported for RFA [5], 88% and 67% versus 47% and 39%,
respectively. This was also presumably because in our study the
tumors were 3 cm or less, whereas the previous RFA study
included tumors which were 3–4 cm. In our study, there were 6
patients with disease progression other than local recurrence, but
the number of patients was too small to evaluate if there is any
characteristic pattern of disease progression after lung cancer
cryoablation.
Determination of medical inoperability is critically important
and should be assessed by an interdisciplinary team. A patient
should not be judged as inoperable by one factor alone, such as
poor pulmonary function. Therefore the assessment of medical
operability requires a comprehensive evaluation of multiple factors
in the patient. To this end, the group of patients in the present
study all had significant associated comorbidities, with CCIs of
.=3. This score has been validated in surgically resected patients
with lung cancer [15,16]. In these reports, multivariate analysis
showed that a CCI .=3 was a significant predictive factor of
increased risk of major complications. In the current study, the
patients who underwent cryoablation were elderly (median age, 72
years), had significant comorbidities (mean CCI, 5), and therefore,
were considered to represent a high-risk population for surgery.
Although further follow-up is needed, so far only one patient in
this study has died of lung cancer, and other 2 patients have died
of their comorbidities. This result suggests that minimally invasive
treatment options such as cryoablation may actually be appropri-
ate for patients with substantial comorbidities.
In terms of efficacy, there is evidence to suggest that
cryoablation may result in improved local control in comparison
to RFA in renal tumors [17], but to our knowledge there are no
studies comparing the two modalities in lung tumors. Since this is a
retrospective, observational study with a relatively short follow-up
in a limited number of highly selected patients subjected to
multiple biases, further studies are necessary to more appropriately
address the outcomes of cryoablation in comparison to RFA for
early stage lung cancer. SBRT is also evolving to be a promising
treatment option for early stage lung cancer, with remarkable
improvements in efficacy and safety. The indications for SBRT
and ablative procedures are expected to be very similar, and
further studies are necessary to delineate the strengths and
weaknesses of each of these modalities, which may be comple-
mentary rather than mutually exclusive.
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